Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NLNK NASDAQ:RIGL NASDAQ:VSTM NASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNLNKNewLink Genetics$9.07$0.82▼$3.60$162.00M1.17547,540 shsN/ARIGLRigel Pharmaceuticals$37.96+0.4%$30.15$13.01▼$43.72$678.38M1.27749,294 shs379,731 shsVSTMVerastem$9.72+4.0%$7.25$2.54▼$11.24$575.45M0.932.55 million shs1.77 million shsXOMAXOMA Royalty$37.42-0.8%$29.90$18.35▼$38.00$455.95M0.9956,364 shs28,668 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNLNKNewLink Genetics0.00%0.00%0.00%0.00%+22.25%RIGLRigel Pharmaceuticals+0.37%-8.18%+3.77%+84.99%+192.68%VSTMVerastem+3.96%-9.75%+21.20%+73.57%+247.14%XOMAXOMA Royalty-0.80%+6.19%+21.14%+56.90%+37.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNLNKNewLink Genetics$9.07$0.82▼$3.60$162.00M1.17547,540 shsN/ARIGLRigel Pharmaceuticals$37.96+0.4%$30.15$13.01▼$43.72$678.38M1.27749,294 shs379,731 shsVSTMVerastem$9.72+4.0%$7.25$2.54▼$11.24$575.45M0.932.55 million shs1.77 million shsXOMAXOMA Royalty$37.42-0.8%$29.90$18.35▼$38.00$455.95M0.9956,364 shs28,668 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNLNKNewLink Genetics0.00%0.00%0.00%0.00%+22.25%RIGLRigel Pharmaceuticals+0.37%-8.18%+3.77%+84.99%+192.68%VSTMVerastem+3.96%-9.75%+21.20%+73.57%+247.14%XOMAXOMA Royalty-0.80%+6.19%+21.14%+56.90%+37.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNLNKNewLink Genetics 0.00N/AN/AN/ARIGLRigel Pharmaceuticals 2.40Hold$38.200.63% UpsideVSTMVerastem 3.00Buy$13.2936.68% UpsideXOMAXOMA Royalty 3.33Buy$69.5085.73% UpsideCurrent Analyst Ratings BreakdownLatest NLNK, RIGL, VSTM, and XOMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025XOMAXOMA RoyaltyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/9/2025VSTMVerastemBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/25/2025VSTMVerastemB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/12/2025VSTMVerastemZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/12/2025XOMAXOMA RoyaltyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/8/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $13.008/6/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$23.00 ➝ $32.006/25/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNLNKNewLink Genetics$940K0.00N/AN/A$2.11 per share0.00RIGLRigel Pharmaceuticals$267.92M2.54$1.08 per share35.06$0.19 per share199.79VSTMVerastem$10K59,816.88N/AN/A($0.65) per share-14.95XOMAXOMA Royalty$28.49M15.88N/AN/A$6.95 per share5.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNLNKNewLink Genetics-$42.99M-$1.03N/AN/AN/A-4,592.84%-41.50%-33.95%N/ARIGLRigel Pharmaceuticals$17.49M$5.417.0236.15N/A36.51%438.89%57.03%11/6/2025 (Estimated)VSTMVerastem-$130.64M-$3.28N/AN/AN/AN/A-2,003.62%-119.85%11/5/2025 (Estimated)XOMAXOMA Royalty-$13.82M-$1.55N/AN/AN/A-27.57%2.63%0.97%11/6/2025 (Estimated)Latest NLNK, RIGL, VSTM, and XOMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025XOMAXOMA Royalty-$0.12$0.48+$0.60$0.44$9.39 million$13.13 million8/7/2025Q2 2025VSTMVerastem-$0.64-$0.39+$0.25-$0.39$6.01 million$2.14 million8/5/2025Q2 2025RIGLRigel Pharmaceuticals$1.97$3.28+$1.31$3.28$64.58 million$101.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNLNKNewLink GeneticsN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNLNKNewLink GeneticsN/A7.987.98RIGLRigel Pharmaceuticals0.462.021.90VSTMVerastem2.063.463.44XOMAXOMA Royalty1.414.884.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNLNKNewLink Genetics32.32%RIGLRigel Pharmaceuticals66.23%VSTMVerastem88.37%XOMAXOMA Royalty95.92%Insider OwnershipCompanyInsider OwnershipNLNKNewLink Genetics12.70%RIGLRigel Pharmaceuticals9.48%VSTMVerastem2.10%XOMAXOMA Royalty9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNLNKNewLink Genetics5537.33 millionN/ANot OptionableRIGLRigel Pharmaceuticals16017.94 million16.24 millionOptionableVSTMVerastem5061.54 million60.25 millionOptionableXOMAXOMA Royalty1012.09 million10.99 millionOptionableNLNK, RIGL, VSTM, and XOMA HeadlinesRecent News About These CompaniesThe Pharma Letter M&A roundup - August 2025September 9, 2025 | thepharmaletter.comTNuveen LLC Invests $286,000 in XOMA Royalty Corporation $XOMASeptember 8, 2025 | marketbeat.comXOMA Royalty Corporation $XOMA Shares Sold by BVF Inc. ILSeptember 5, 2025 | marketbeat.comWall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should KnowSeptember 3, 2025 | zacks.comXOMA Royalty Corporation Executives to Present Company Update at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | quiverquant.comQXOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comHere's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock NowSeptember 1, 2025 | zacks.comQ3 EPS Estimates for XOMA Royalty Lifted by HC WainwrightAugust 26, 2025 | marketbeat.comHC Wainwright Predicts Stronger Earnings for XOMA RoyaltyAugust 24, 2025 | marketbeat.comXoma’s Strategic Acquisitions and Innovative Financial Strategies Drive Buy RatingAugust 22, 2025 | tipranks.comMural Oncology and XOMA Royalty Corporation Announce Definitive Agreement for Acquisition of Mural OncologyAugust 20, 2025 | quiverquant.comQMural Oncology to be acquired by XOMA unit for up to $2.24/share in cashAugust 20, 2025 | seekingalpha.comMural Oncology Enters Definitive Agreement for Acquisition by XOMA Royalty Corporation in Cash Deal Valued at Approximately $36.2 MillionAugust 20, 2025 | quiverquant.comQMural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per ShareAugust 20, 2025 | globenewswire.comQ3 EPS Estimates for XOMA Royalty Reduced by Leerink PartnrsAugust 19, 2025 | marketbeat.comHow Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%August 18, 2025 | zacks.comLeerink Partnrs Raises Earnings Estimates for XOMA RoyaltyAugust 17, 2025 | marketbeat.comXOMA Royalty (NASDAQ:XOMA) Rating Increased to Hold at Zacks ResearchAugust 17, 2025 | marketbeat.comXOMA Royalty (NASDAQ:XOMA) Releases Earnings Results, Beats Estimates By $0.60 EPSAugust 16, 2025 | marketbeat.comXOMA Royalty Corporation Beat Analyst Profit Forecasts, And Analysts Have New EstimatesAugust 16, 2025 | finance.yahoo.comLAVA Therapeutics Announces Acquisition by XOMA CorporationAugust 14, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNLNK, RIGL, VSTM, and XOMA Company DescriptionsNewLink Genetics NASDAQ:NLNKNewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.Rigel Pharmaceuticals NASDAQ:RIGL$37.96 +0.14 (+0.37%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$38.00 +0.04 (+0.11%) As of 09/12/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Verastem NASDAQ:VSTM$9.72 +0.37 (+3.96%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$9.77 +0.05 (+0.50%) As of 09/12/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.XOMA Royalty NASDAQ:XOMA$37.42 -0.30 (-0.80%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$37.48 +0.06 (+0.16%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
